Genome-Wide Association Study of Prognosis in Advanced Non-Small Cell Lung Cancer Patients Receiving Platinum-based Chemotherapy
Clinical Cancer Research, 08/08/2012
Hu L et al. – In this three–stage genome–wide association studies (GWAS), the authors identified five single nucleotide polymorphisms (SNP) as markers for survival of advanced–stage non–small–cell lung cancer (NSCLC) patients treated with first–line platinum–based chemotherapy in Chinese Han populations. Two of these SNPs, rs7629386 and rs3850370, could also be markers for survival among Caucasian patients.